Indian company Intas Pharmaceuticals has agreed to buy the assets and operations of Actavis Generics in the UK and Ireland from Israeli drugs giant Teva for £603 million ($762 million).
The deal is part of the European Commission’s anti-trust divestiture requirements arising from Teva’s $40.5 billion acquisition of Actavis Generics from Ireland-incorporated Allergan earlier this year.
"This acquisition will make Accord a leading generics player in the UK market"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze